- Home
- TWO vs DVAX Comparison
TWO vs DVAX Comparison
Compare TWO & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWO
- DVAX
- Stock Information
- Founded
- TWO 2009
- DVAX 1996
- Country
- TWO United States
- DVAX United States
- Employees
- TWO N/A
- DVAX N/A
- Industry
- TWO Real Estate Investment Trusts
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- TWO Real Estate
- DVAX Health Care
- Exchange
- TWO Nasdaq
- DVAX Nasdaq
- Market Cap
- TWO 1.1B
- DVAX 1.3B
- IPO Year
- TWO 2009
- DVAX 2004
- Fundamental
- Price
- TWO $10.46
- DVAX $11.36
- Analyst Decision
- TWO Buy
- DVAX Buy
- Analyst Count
- TWO 8
- DVAX 4
- Target Price
- TWO $13.07
- DVAX $26.25
- AVG Volume (30 Days)
- TWO 2.4M
- DVAX 1.6M
- Earning Date
- TWO 07-28-2025
- DVAX 08-05-2025
- Dividend Yield
- TWO 17.22%
- DVAX N/A
- EPS Growth
- TWO N/A
- DVAX N/A
- EPS
- TWO N/A
- DVAX N/A
- Revenue
- TWO $370,696,000.00
- DVAX $294,620,000.00
- Revenue This Year
- TWO N/A
- DVAX $21.18
- Revenue Next Year
- TWO N/A
- DVAX $16.83
- P/E Ratio
- TWO N/A
- DVAX N/A
- Revenue Growth
- TWO N/A
- DVAX 24.76
- 52 Week Low
- TWO $9.76
- DVAX $9.22
- 52 Week High
- TWO $14.28
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- TWO 50.83
- DVAX 66.09
- Support Level
- TWO $9.76
- DVAX $10.38
- Resistance Level
- TWO $10.51
- DVAX $11.48
- Average True Range (ATR)
- TWO 0.20
- DVAX 0.30
- MACD
- TWO 0.05
- DVAX 0.08
- Stochastic Oscillator
- TWO 88.61
- DVAX 90.40
About TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.